Skip to main content

Renflexis News

Top-Down Treatment Superior for Crohn Disease

TUESDAY, March 5, 2024 – Top-down treatment for Crohn disease (combination infliximab plus immunomodulator) achieves substantially better outcomes than accelerated step-up treatment, according to a...

Higher Visceral Adipose Tissue May Need Higher Infliximab Levels for IBD Remission

WEDNESDAY, Nov. 15, 2023 – Patients with inflammatory bowel disease (IBD) and high visceral adipose tissue (VAT) may have more difficulty achieving higher infliximab levels necessary to achieve...

Updated FDA Labeling Recommendations for Biosimilar and Interchangeable Biosimilar Products

October 26, 2023 – Over the last eight years, FDA has approved more than 40 biosimilar products (biosimilars), and they have become an important treatment option for health care professionals and...

FDA Approves Avsola (infliximab-axxq), a Biosimilar to Remicade

THOUSAND OAKS, Calif., Dec. 6, 2019 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Avsola (infliximab-axxq) for all approved...

FDA Approves Ixifi (infliximab-qbtx), a Biosimilar to Remicade

December 13, 2017 – Pfizer Inc. (NYSE:PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved Ixifi (PF-06438179, infliximab-qbtx), a chimeric...

FDA Approves Renflexis (infliximab-abda), a Biosimilar to Remicade

INCHEON, Korea – April 24, 2017 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Renflexis (infliximab-abda), a biosimilar referencing Rem...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Ankylosing Spondylitis, Crohn's Disease, Inflammatory Bowel Disease, Plaque Psoriasis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis

Renflexis patient information at Drugs.com